Silencing disease genes in the laboratory and the clinic

Untitled work

Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456

Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing

Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008) · Nature Genetics · doi:10.1038/ng.259 · Cited by 3,951

Silencing of microRNAs in vivo with ‘antagomirs’

Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949

Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide

Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332

RNA interference is mediated by 21- and 22-nucleotide RNAs

Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310

Knocking down barriers: advances in siRNA delivery

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505

Expression profiling reveals off-target gene regulation by RNAi

Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082

Rational design of cationic lipids for siRNA delivery

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620

LNA-mediated microRNA silencing in non-human primates

Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589

Targeting microRNAs in cancer: rationale, strategies and challenges

Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459

miR2Disease: a manually curated database for microRNA deregulation in human disease

Jiang, Q., Wang, Y., Hao, Y., Juan, L., Teng, M., Zhang, X., Li, M., Wang, G., & Liu, Y. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn714 · Cited by 1,422

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168

Morpholino Antisense Oligomers: Design, Preparation, and Properties

SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116

LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition

Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021

Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity

Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956

Sequence- and target-independent angiogenesis suppression by siRNA via TLR3

Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924

Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.

Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906

An Analysis of Human MicroRNA and Disease Associations

Lu, M., Zhang, Q., Deng, M., Miao, J., Guo, Y., Gao, W., & Cui, Q. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003420 · Cited by 902

miRNAs in human cancer

Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011) · The Journal of Pathology · doi:10.1002/path.2806 · Cited by 895

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy

Kim, D.-H., Behlke, M. A., Rose, S. D., Chang, M.-S., Choi, S., & Rossi, J. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1051 · Cited by 884

Delivery of siRNA Therapeutics: Barriers and Carriers

Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798

Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing

Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789

Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression

Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778

Telomerase and cancer therapeutics

Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728

Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides

Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700

Aptamers come of age – at last

Bunka, D. H. J., & Stockley, P. G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1458 · Cited by 695

The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes

Freier, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.22.4429 · Cited by 692

Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy

Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678

On the road to reading the RNA-interference code

Siomi, H., & Siomi, M. C. (2009) · Nature · doi:10.1038/nature07754 · Cited by 675

Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model

Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664

Lipid-based Nanoparticles for Nucleic Acid Delivery

Li, W., & Szoka, F. C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9180-5 · Cited by 641

Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing

MEISTER, G., LANDTHALER, M., DORSETT, Y., & TUSCHL, T. (2004) · RNA · doi:10.1261/rna.5235104 · Cited by 621

Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone

Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 609

Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA

Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589

Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo

Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571

Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs

Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt.1543 · Cited by 534

Potent and nontoxic antisense oligonucleotides containing locked nucleic acids

Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520

Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology

Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494

Off-target effects by siRNA can induce toxic phenotype

Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.28106 · Cited by 490

A Primer for Morpholino Use in Zebrafish

Bill, B. R., Petzold, A. M., Clark, K. J., Schimmenti, L. A., & Ekker, S. C. (2009) · Zebrafish · doi:10.1089/zeb.2008.0555 · Cited by 474

Nonviral delivery of synthetic siRNAs in vivo

Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464

Targeted Inhibition of miRNA Maturation with Morpholinos Reveals a Role for miR-375 in Pancreatic Islet Development

Kloosterman, W. P., Lagendijk, A. K., Ketting, R. F., Moulton, J. D., & Plasterk, R. H. A. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050203 · Cited by 464

Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Chiang, M. Y., Chan, H., Zounes, M. A., Freier, S. M., Lima, W. F., & Bennett, C. F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55250-9 · Cited by 463

Lipid-based systemic delivery of siRNA

Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463

siRNA and Innate Immunity

Robbins, M., Judge, A., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 449

Fully 2‘-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA

Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 448

Uniformly modified 2'-deoxy-2'-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets

Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 438

A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

Levin, A. A. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00140-2 · Cited by 438

Chemically modified siRNA: tools and applications

Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431

Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides

Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429

Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.

Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426

MicroRNAs in Disease and Potential Therapeutic Applications

Soifer, H. S., Rossi, J. J., & Sætrom, P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300311 · Cited by 394

5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387 · cited 1×

Design of a genome-wide siRNA library using an artificial neural network

Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1118 · Cited by 386

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380

miR-122, a paradigm for the role of microRNAs in the liver

Girard, M., Jacquemin, E., Munnich, A., Lyonnet, S., & Henrion-Caude, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.019 · Cited by 375

LNA-modified oligonucleotides mediate specific inhibition of microRNA function

Ørom, U. A., Kauppinen, S., & Lund, A. H. (2006) · Gene · doi:10.1016/j.gene.2005.12.031 · Cited by 373

A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity

Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 360

Activation of the mammalian immune system by siRNAs

Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 358

Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs

Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349

Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion protein

Eguchi, A., Meade, B. R., Chang, Y.-C., Fredrickson, C. T., Willert, K., Puri, N., & Dowdy, S. F. (2009) · Nature Biotechnology · doi:10.1038/nbt.1541 · Cited by 340

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336

siRNA Selection Server: an automated siRNA oligonucleotide prediction server

Yuan, B., Latek, R., Hossbach, M., Tuschl, T., & Lewitter, F. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh366 · Cited by 307

The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides

Kretschmer-Kazemi Far, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg649 · Cited by 291

Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†

Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290

Chemical modification: the key to clinical application of RNA interference?

Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285

Overcoming the Innate Immune Response to Small Interfering RNA

Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281

Overexpression of Exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs

YI, R., DOEHLE, B. P., QIN, Y., MACARA, I. G., & CULLEN, B. R. (2005) · RNA · doi:10.1261/rna.7233305 · Cited by 278

Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA

Grunweller, A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg409 · Cited by 269

Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications

Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267

Selecting effective antisense reagents on combinatorial oligonucleotide arrays

Milner, N., Mir, K. U., & Southern, E. M. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-537 · Cited by 261

Inhibition of microRNA with antisense oligonucleotides

Esau, C. C. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 257

DNA Analogues: From Supramolecular Principles to Biological Properties

Leumann, C. J. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00348-0 · Cited by 256

miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates

Fabani, M. M., & Gait, M. J. (2008) · RNA · doi:10.1261/rna.844108 · Cited by 252

Morpholino, siRNA, and S-DNA Compared: Impact of Structure and Mechanism of Action on Off-Target Effects and Sequence Specificity

Summerton, J. E. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780487740 · Cited by 251

Biodistribution of phosphodiester and phosphorothioate siRNA

Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Öz, O. K., Mason, R. P., & Corey, D. R. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.074 · Cited by 251

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates

Straarup, E. M., Fisker, N., Hedtjärn, M., Lindholm, M., Rosenbohm, C., Aarup, V., Hansen, H. F., Ørum, H., Hansen, J. B., & Koch, T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq457 · Cited by 248

Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice

Jearawiriyapaisarn, N., Moulton, H. M., Buckley, B. K., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P. L., & Kole, R. (2008) · Molecular Therapy · doi:10.1038/mt.2008.120 · Cited by 245

The use of single-stranded DNA and RNase H to promote quantitative ‘hybrid arrest of translation’ of mRNA/DNA hybrids in reticulocyte lysate cell-free translations

Minshull, J., & Hunt, T. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.16.6433 · Cited by 243

Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer

Wu, B., Moulton, H. M., Iversen, P. L., Jiang, J., Li, J., Li, J., Spurney, C. F., Sali, A., Guerron, A. D., Nagaraju, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805676105 · Cited by 236

Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide

Martin, P. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780219 · Cited by 234

Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy

Moulton, H. M., & Moulton, J. D. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.02.012 · Cited by 229

Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting

De Paula, D., Bentley, M. V. L. B., & Mahato, R. I. (2007) · RNA · doi:10.1261/rna.459807 · Cited by 228

Problems in Interpretation of Data Derived from in Vitro and in Vivo Use of Antisense Oligodeoxynucleotides

Stein, C. A., & Krieg, A. M. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.67 · Cited by 228

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 225

Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function

Yin, H., Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., & Wood, M. J. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn293 · Cited by 224

Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation

Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.131 · Cited by 220

siRNA and isRNA: two edges of one sword

Schlee, M., Hornung, V., & Hartmann, G. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.06.001 · Cited by 217

Pharmacokinetics, Biodistribution, Stability and Toxicity of a Cell-Penetrating Peptide−Morpholino Oligomer Conjugate

Amantana, A., Moulton, H. M., Cate, M. L., et al. (2007) · Bioconjugate Chemistry · doi:10.1021/bc070060v · Cited by 215

Potent inhibition of microRNA in vivo without degradation

Davis, S. P., Propp, S. S., Freier, S. M., Jones, L., Serra, M. J., Kinberger, G. A., Bhat, B., Swayze, E. E., Bennett, C. F., & Esau, C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn904 · Cited by 203

Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region

Azad, R. F., Brown‐Driver, V., Tanaka, K., Crooke, R. M., & Anderson, K. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1945 · Cited by 203

Sequence-non-specific effects of RNA interference triggers and microRNA regulators

Olejniczak, M., Galka, P., & Krzyzosiak, W. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp829 · Cited by 202

How does RNase H recognize a DNA.RNA hybrid?

Nakamura, H., Oda, Y., Iwai, S., Inoue, H., Ohtsuka, E., Kanaya, S., Kimura, S., Katsuda, C., Katayanagi, K., & Morikawa, K. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11535 · Cited by 193

Improved silencing properties using small internally segmented interfering RNAs

Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W., Ravindra Babu, B., Wengel, J., & Kjems, J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm548 · Cited by 192

2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug

Morita, K., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., & Koizumi, M. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00683-7 · Cited by 188

Morpholino antisense oligonucleotides: tools for investigating vertebrate development.

Corey, D. R., & Abrams, J. (2001) · Genome biology · doi:10.1186/gb-2001-2-5-reviews1015 · Cited by 188

Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries

Ho, S. P., Bao, Y., Lesher, T., Malhotra, R., Ma, L. Y., Fluharty, S. J., & Sakai, R. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0198-59 · Cited by 186

Hybrids of RNA and Arabinonucleic Acids (ANA and 2‘F-ANA) Are Substrates of Ribonuclease H

Damha, M. J., Wilds, C. J., Noronha, A., Brukner, I. B., Borkow, G., Arion, D., & Parniak, M. A. (1998) · Journal of the American Chemical Society · doi:10.1021/ja982325+ · Cited by 179

Targeted delivery of siRNA to macrophages for anti-inflammatory treatment.

Kim, S.-S., Ye, C., Kumar, P., Chiu, I., Subramanya, S., Wu, H., Shankar, P., & Manjunath, N. (2010) · Molecular Therapy · doi:10.1038/mt.2010.27 · Cited by 176

Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity

Chen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176

Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect

Ui-Tei, K., Naito, Y., Zenno, S., Nishi, K., Yamato, K., Takahashi, F., Juni, A., & Saigo, K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn042 · Cited by 176

Therapeutic Applications of DNA and RNA Aptamers

Thiel, K. W., & Giangrande, P. H. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0199 · Cited by 173

Whither RNAi?

(2003) · Nature Cell Biology · doi:10.1038/ncb0603-490 · Cited by 153

Erratum: Corrigendum: Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs

Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt0709-671a · Cited by 151

Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

Grimm, D., & Kay, M. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34129 · Cited by 151

Therapeutic Potential of Splice-Switching Oligonucleotides

Bauman, J. A., Jearawiriyapaisarn, N., & Kole, R. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0161 · Cited by 150

RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy

Alvarez, R., Elbashir, S. M., Borland, T. D., Toudjarska, I., Hadwiger, P., John, M., Roehl, I., Shulga‐Morskaya, S., Martinello, R., Kahn, J. S., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00014-09 · Cited by 149

The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines

Joseph, I., Tressler, R., Bassett, E., Harley, C. B., Buseman, C. M., Pattamatta, P., Wright, W. E., Shay, J. W., & Go, N. F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0233 · Cited by 147

Anti-tumor activity of splice-switching oligonucleotides

Bauman, J. A., Li, S., Yang, A., Huang, L., & Kole, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq731 · Cited by 141

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice

Yin, H., Moulton, H. M., Betts, C., Seow, Y., Boutilier, J. K., Iverson, P. L., & Wood, M. J. A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp395 · Cited by 137

“Antisense Drug Technology. Principles, Strategies, and Applications”

Lee, G. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00090-5 · Cited by 135

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

Zoubeidi, A., Chi, K., & Gleave, M. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2917 · Cited by 134

Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.

Geary, R. S., Yu, R. Z., & Levin, A. A. (2001) · PubMed · Cited by 133

Synthetic agonists of Toll-like receptors 7, 8 and 9

Agrawal, S., & Kandimalla, E. R. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351461 · Cited by 128

Enhanced Peptide Nucleic Acid Binding to Supercoiled DNA: Possible Implications for DNA “Breathing” Dynamics

Bentin, T., & Nielsen, P. E. (1996) · Biochemistry · doi:10.1021/bi960436k · Cited by 120

Asymmetric Shorter-duplex siRNA Structures Trigger Efficient Gene Silencing With Reduced Nonspecific Effects

Chang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S., Sun, X., Rogoff, H. A., Ban, C., Kim, S., Li, C. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.298 · Cited by 120

Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)

Watanabe, T. A., Geary, R. S., & Levin, A. A. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.169 · Cited by 120

Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection

Sano, M., Sierant, M., Miyagishi, M., Nakanishi, M., Takagi, Y., & Sutou, S. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn584 · Cited by 120

Competition for RISC binding predicts in vitro potency of siRNA

Koller, E., Propp, S. S., Murray, H., Lima, W. F., Bhat, B., Prakash, T. P., Allerson, C. R., Swayze, E. E., Marcusson, E. G., & Dean, N. M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl589 · Cited by 115

Asymmetric RNA duplexes mediate RNA interference in mammalian cells

Sun, X., Rogoff, H. A., & Li, C. J. (2008) · Nature Biotechnology · doi:10.1038/nbt.1512 · Cited by 114

Chemical Modification Patterns Compatible with High Potency Dicer-Substrate Small Interfering RNAs

Collingwood, M. A., Rose, S. D., Huang, L., Hillier, C., Amarzguioui, M., Wiiger, M. T., Soifer, H. S., Rossi, J. J., & Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0123 · Cited by 105

RNA learns from antisense

Corey, D. R. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0107-8 · Cited by 97

Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing

Deleavey, G. F., Watts, J. K., Alain, T., Robert, F., Kalota, A., Aishwarya, V., Pelletier, J., Gewirtz, A. M., Sonenberg, N., & Damha, M. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq181 · Cited by 97

Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region.

Bacon, T. A., & Wickstrom, E. (1991) · PubMed · Cited by 92

Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation

Spiller, D. G., Giles, R. V., Grzybowski, J., et al. (1998) · Blood · doi:10.1182/blood.v91.12.4738.412k31_4738_4746 · Cited by 91

Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices

Stull, R. A., Taylor, L. A., & Szoka, F. C. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.13.3501 · Cited by 87

The Business of RNAi Therapeutics

Haussecker, D. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.007 · Cited by 87

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers†

Jearawiriyapaisarn, N., Moulton, H. M., Sazani, P., et al. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp335 · Cited by 85

Properties of 2'-fluorothymidine-containing oligonucleotides: interaction with restriction endonuclease EcoRV

Williams, D. M., Benseler, F., & Eckstein, F. (1991) · Biochemistry · doi:10.1021/bi00230a027 · Cited by 83

Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO

Yin, H., Moulton, H. M., Betts, C., Merritt, T. M., Seow, Y., Ashraf, S., Wang, Q., Boutilier, J. K., & Wood, M. J. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.151 · Cited by 81

In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1

Rittner, K., Burmester, C., & Sczakiel, G. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.6.1381 · Cited by 81

Repair of a Splicing Defect in Erythroid Cells from Patients with β-Thalassemia/HbE Disorder

Suwanmanee, T., Sierakowska, H., Fucharoen, S., & Kole, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0805 · Cited by 76

Five- and Six-Membered Conformationally Locked 2‘,4‘-Carbocyclicribo-Thymidines: Synthesis, Structure, and Biochemical Studies

Srivastava, P., Barman, J., Pathmasiri, W., Plashkevych, O., Wenska, M., & CHATTOPADHYAYA, J. B. (2007) · Journal of the American Chemical Society · doi:10.1021/ja071106y · Cited by 74

Rational design of immunostimulatory siRNAs.

Gantier, M., Tong, S., Behlke, M., Irving, A. T., Lappas, M., Nilsson, U., Latz, E., McMillan, N., & Williams, B. (2010) · Molecular Therapy · doi:10.1038/mt.2010.4 · Cited by 72

Synthesis and properties of 2′-O,4′-C-methyleneoxymethylene bridged nucleic acid

Hari, Y., Obika, S., Ohnishi, R., Eguchi, K., Osaki, T., Ohishi, H., & Imanishi, T. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.020 · Cited by 72

Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection

Zhang, Y., Qu, Z., Kim, S., Shi, V., Liao, B., Kraft, P., Bandaru, R., Wu, Y. S., Greenberger, L. M., & Horak, I. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.133 · Cited by 71

Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge

Smulevitch, S. V., Simmons, C. G., Norton, J. C., Wise, T. W., & Corey, D. R. (1996) · Nature Biotechnology · doi:10.1038/nbt1296-1700 · Cited by 70

2′F-Arabinonucleic acids (2′F-ANA) — History, properties, and new frontiers

Watts, J. K., & Damha, M. J. (2008) · Canadian Journal of Chemistry · doi:10.1139/v08-049 · Cited by 69

Fomivirsen

Grillone, L. R., & Lanz, R. (2001) · Drugs of today · doi:10.1358/dot.2001.37.4.620590 · Cited by 69

Mechanistic Insights Aid Computational Short Interfering RNA Design

Boese, Q., Leake, D., Reynolds, A., Read, S., Scaringe, S. A., Marshall, W. S., & Khvorova, A. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)92005-8 · Cited by 68

A Novel Class of Oligonucleotide Analogues Containing 2‘-O,3‘-C-Linked [3.2.0]Bicycloarabinonucleoside Monomers: Synthesis, Thermal Affinity Studies, and Molecular Modeling

Christensen, N. K., Petersen, M. Å., Nielsen, P., Jacobsen, J., Olsen, C. E., & Wengel, J. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9743598 · Cited by 67

Restoration of Human β-Globin Gene Expression in Murine and Human IVS2–654 Thalassemic Erythroid Cells by Free Uptake of Antisense Oligonucleotides

Suwanmanee, T., Sierakowska, H., Lacerra, G., Svasti, S., Kirby, S. L., Walsh, C., Fucharoen, S., & Kole, R. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.545 · Cited by 66

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides

Stewart, A. J., Canitrot, Y., Baracchini, E., Dean, N. M., Deeley, R. G., & Cole, S. P. C. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02220-1 · Cited by 66

Developments in RNA chemistry, a personal view

Eckstein, F. (2002) · Biochimie · doi:10.1016/s0300-9084(02)01459-1 · Cited by 65

Clinical status of duplex RNA

Watts, J. K., & Corey, D. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.109 · Cited by 62

Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging

Bergan, R. C., Hakim, F. T., Schwartz, G., Kyle, E., Cepada, R., Szabo, J., Fowler, D. H., Gress, R. E., & Neckers, L. (1996) · Blood · doi:10.1182/blood.v88.2.731.bloodjournal882731 · Cited by 61

siRNA‐induced immunostimulation through TLR7 promotes antitumoral activity against HPV‐driven tumors in vivo

Khairuddin, N., Gantier, M., Blake, S., Wu, S., Behlke, M., Williams, B. R. G., & McMillan, N. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2011.19 · Cited by 50

Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs

Levin, A. A., Yu, R. Z., & Geary, R. S. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-14 · Cited by 47

Characterization of Antisense Oligonucleotides Comprising 2′‐Deoxy‐2′‐Fluoro‐β‐ d ‐Arabinonucleic Acid (FANA)

FERRARI, N., BERGERON, D., Tedeschi, A. L., Mangos, M., Paquet, L., RENZI, P. M., & Damha, M. J. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.032 · Cited by 40

Therapeutic Advances in MicroRNA Targeting

Montgomery, R. L., & van Rooij, E. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181f603d0 · Cited by 40

Modification of HER2 pre‐mRNA alternative splicing and its effects on breast cancer cells

Wan, J., Sazani, P., & Kole, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.24052 · Cited by 40

Safety signal dampens reception for mipomersen antisense

Kling, J. (2010) · Nature Biotechnology · doi:10.1038/nbt0410-295 · Cited by 38

Theoretical and Experimental Approaches to Design Effective Antisense Oligonucleotides

Sczakiel, G. (2000) · Frontiers in bioscience · doi:10.2741/a504 · Cited by 31

Antisense—down, but not out

Potera, C. (2007) · Nature Biotechnology · doi:10.1038/nbt0507-497 · Cited by 31

RNAi momentum fizzles as pharma shifts priorities

Schmidt, C. (2011) · Nature Biotechnology · doi:10.1038/nbt0211-93 · Cited by 29

Effects of local mRNA structure on posttranscriptional gene silencing

Rudnick, S. I., Swaminathan, J., Sumaroka, M. V., Liebhaber, S. A., & Gewirtz, A. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805781105 · Cited by 28

A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5′ RACE and a molecular beacon probe

Lasham, A., Herbert, M., Coppieters, N., Patel, R., Feng, S. X., Eszes, M., Cao, H., & Reid, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1076 · Cited by 24

Atomic Glimpses on a Billion-Year-Old Molecular Machine

Westhof, É., & Leontis, N. B. (2000) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(20000502)39:9<1656::aid-anie1656>3.0.co;2-q · Cited by 20

Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules

Gifford, L. K., Opalinska, J. B., Jordan, D., Pattanayak, V., Greenham, P., Kalota, A., Robbins, M., Vernovsky, K., Rodriguez, L. C., Do, B. T., et al. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni024 · Cited by 20

Potent and systematic RNAi mediated silencing with single oligonucleotide compounds

Lapierre, J., Salomon, W. E., Cardia, J. P., Bulock, K. G., Lam, J. T., Stanney, W., Ford, G., Smith-Anzures, B., Woolf, T. M., Kamens, J., et al. (2011) · RNA · doi:10.1261/rna.2399411 · Cited by 8

RNAi Gets Vote of Confidence from Big Pharma

Frederickson, R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300099 · Cited by 4

Antisense Oligonucleotides: Insights from Preclinical Studies and Clinical Trials

Kunze, D., Kraemer, K., & Fuessel, S. (2010) · RNA technologies · doi:10.1007/978-3-642-12168-5_13 · Cited by 3

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349

Epigenetics of colorectal cancer: biomarker and therapeutic potential

Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813

The delivery of therapeutic oligonucleotides

Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854

An overview of COVID-19

Shi, Y., Wang, G., Cai, X.-P., Deng, J.-W., Zheng, L., Zhu, H.-H., Zheng, M., Yang, B., & Chen, Z. (2020) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b2000083 · Cited by 580

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01634-w · Cited by 239